Company profile: SOM Biotech
1.1 - Company Overview
Company description
- Provider of AI-based drug discovery and drug repurposing for orphan CNS diseases via the SOM AI PRO platform, validated by two successful Phase 2 trials (TTR amyloidosis; chorea in Huntington’s). Pipeline includes SOM3355 (oral VMAT2 inhibitor, Phase 2b), SOM0226 (TTR stabilizer, outlicensed), SOM1311 (PKU chaperone, expected to enter Phase 2a in 2024), and SOM0034 (DMD program, Phase 2 expected 2025).
Products and services
- SOMAIPRO: Proprietary AI-based platform that discovers new indications for existing drugs and identifies drugs for specific indications, validated by two successful Phase 2 trials in TTR amyloidosis and Huntington’s chorea
- SOM3355: Clinical-stage oral VMAT2 inhibitor that mitigates chorea symptoms in Huntington’s disease, currently advancing through Phase 2b clinical trial development
- SOM0226: Small-molecule TTR stabilizer that stabilizes transthyretin to treat TTR amyloidosis, outlicensed and in development for various disease forms
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SOM Biotech
Spectral Medical
HQ: Canada
Website
- Description: Provider of therapies and diagnostics for septic shock and sepsis risk, including Toraymyxin (PMX) hemoperfusion to remove endotoxin and the Endotoxin Activity Assay (EAA). Conducts the Tigris Phase 3 study of PMX with standard care. Also offers the DIMI hemodialysis system for continuous renal replacement therapy, licensed for hospitals, clinics, and homes in Canada and the USA, and the SAMI device for continuous renal replacement therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spectral Medical company profile →
Nabriva Therapeutics
HQ: Austria
Website
- Description: Provider of innovative anti-infective agents to treat serious infections, including XENLETA (lefamulin) for adult CABP, IV and oral, FDA-approved; CONTEPO (fosfomycin) IV for complicated urinary tract infections, including acute pyelonephritis, active against multi-drug resistant strains; and BC-7013, a topical pleuromutilin candidate for Gram-positive infections, including uncomplicated skin and skin structure infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nabriva Therapeutics company profile →
Genticel
HQ: France
Website
- Description: Provider of therapeutic vaccines and innovative immunotherapies to treat virus infections and virus-induced diseases, with an initial focus on HPV and HPV-induced conditions, including prevention of cervical cancer in HPV-infected women.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genticel company profile →
Achillion Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies targeting the complement system, including Soliris for paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uraemic syndrome (aHUS) and neuromyelitis optica spectrum disorder; Ultomiris, a long-acting C5 complement inhibitor, for PNH, aHUS, generalised myasthenia gravis and NMOSD; and Strensiq for hypophosphatasia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Achillion Pharmaceuticals company profile →
Brii Biosciences
HQ: United States
Website
- Description: Provider of innovative medicines developed to improve public health in China, focusing on treatment options and preventive measures for Hepatitis B (prevention in Asia-Pacific excluding Japan), HIV therapies, NTM lung disease (Greater China rights), MDR/XDR Gram-negative bacterial infections (with Monash University), and anxiety and depressive disorders via internally discovered programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Brii Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SOM Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SOM Biotech
2.2 - Growth funds investing in similar companies to SOM Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SOM Biotech
4.2 - Public trading comparable groups for SOM Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →